Get the Stockscreener App
13.35
6.21%
0.78
After Hours:
13.60
0.25
+1.87%
Perspective Therapeutics Inc stock is traded at $13.35, with a volume of 1.12M.
It is up +6.21% in the last 24 hours and down -15.51% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$12.57
Open:
$12.7
24h Volume:
1.12M
Relative Volume:
1.22
Market Cap:
$900.16M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-163.60
EPS:
-0.0816
Net Cash Flow:
$-37.99M
1W Performance:
+9.16%
1M Performance:
-15.51%
6M Performance:
+12.18%
1Y Performance:
+387.76%
1-Day Range:
$12.50
$13.43
1-Week Range:
$11.88
$13.43
52-Week Range:
$2.201
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine - The Manila Times
Marshall Wace LLP Trims Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Wall Street SWOT: CATX stock rides radiopharmaceutical wave amid clinical progress - Investing.com India
Wall Street SWOT: CATX stock rides radiopharmaceutical wave amid clinical progress - Investing.com
Deerfield Management Company L.P. Series C Decreases Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Perspective Therapeutics Inc (CATX) can make a big difference with a little luck - SETE News
Perspective Therapeutics Inc [CATX] affiliate makes an insider purchase of 2,500 shares worth 39500.0. - Knox Daily
Truist Securities Initiates Coverage of Perspective Therapeutics (CATX) with Buy Recommendation - MSN
Perspective stock draws buy at Truist (NYSE:CATX) - Seeking Alpha
Perspective Therapeutics (NYSE:CATX) Shares Gap Up to $12.28 - MarketBeat
Perspective Therapeutics (NYSE:CATX) Research Coverage Started at Truist Financial - MarketBeat
Can you still get a good price for Perspective Therapeutics Inc (CATX) Shares at this point? - US Post News
Perspective Therapeutics stock undervalued despite pipeline in oncologyTruist - Investing.com
Affinity Asset Advisors LLC Reduces Position in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
63,170 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Purchased by Rhumbline Advisers - Defense World
Vaxcyte Inc (PCVX) receives a Buy rating from Mizuho - Knox Daily
The time has not yet come to remove your chips from the table: Vaxcyte Inc (PCVX) - SETE News
Structure Therapeutics Inc ADR (GPCR)’s stock chart: A technical perspective - US Post News
Berkley W R Corp Grows Holdings in Perception Capital Corp. III (NASDAQ:PFTA) - MarketBeat
Ally Bridge Group NY LLC Purchases New Position in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Understanding the Risks of Investing in Perspective Therapeutics Inc (CATX) - Knox Daily
Perspective Therapeutics (NYSE:CATX) Trading Down 5.9% - MarketBeat
Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Investing in Verve Therapeutics Inc (VERV) Is Getting More Attractive - Knox Daily
Upward Trajectory: Perspective Therapeutics Inc (CATX) Posts a Slidee, Closing at 13.23 - The Dwinnex
HighVista Strategies LLC Buys New Shares in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Investing in P3 Health Partners Inc (PIII): What You Must Know - Knox Daily
Structure Therapeutics’ (GPCR) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
PTC (NASDAQ:PTC) & WiMi Hologram Cloud (NASDAQ:WIMI) Head to Head Contrast - Defense World
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index - Marketscreener.com
This under-the-radar value stock could soar 93%, say analysts - MSN
Bank of New York Mellon Corp Has $1.37 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Bank of New York Mellon Corp Buys 93,548 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Taking a look at what insiders are doing to gauge the Perspective Therapeutics Inc (CATX)’s direction - Knox Daily
Vaxcyte Stock Soars to All-Time High of $119.64 Amidst Robust Growth - Investing.com
Vaxcyte, Inc. (NASDAQ:PCVX) Stake Lessened by E Fund Management Co. Ltd. - Defense World
Was Vaxcyte Inc (PCVX)’s session last reading good? - US Post News
Viking Therapeutics Inc [VKTX] Shares Rise 2.40 % on Wednesday - Knox Daily
WINTON GROUP Ltd Acquires New Position in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
Priority Technology (NASDAQ:PRTH) Hits New 52-Week High at $6.90 - Defense World
A better buy-in window may exist right now for Perspective Therapeutics Inc (CATX) - SETE News
Perspective Therapeutics Inc (CATX) rating initates by BofA Securities - Knox Daily
Priority Technology (NASDAQ:PRTH) Shares Gap Up to $6.02 - MarketBeat
Vaxcyte Inc (PCVX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Relmada Therapeutics Inc Inc. (RLMD) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Liquidia Corp [LQDA] Investment Guide: What You Need to Know - Knox Daily
Perspective Therapeutics Inc (CATX)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Sofinnova Investments Inc. - MarketBeat
Behind Perspective Therapeutics Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Perspective Therapeutics Inc (CATX)’s Market Momentum: Closing Strong at 15.10, Down -4.67 - The Dwinnex
Analysts Set Perspective Therapeutics, Inc. (NYSE:CATX) PT at $19.80 - MarketBeat
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Cap:
|
Volume (24h):